Vericel

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vericel (VCEL) reports robust Q4 earnings and eyes market expansion

Vericel (VCEL) closed 2022 with strong financial and business results, setting the stage for continued growth and profitability in 2023.
The company's focus on innovation, market expansion, and financial discipline underscores its commitment to long-term success.
Despite challenges in regulatory approvals and operational timelines, Vericel (VCEL) remains optimistic about its growth prospects and market positioning.

Vericel reports robust Q1 earnings, raises revenue guidance significantly

Vericel's Q1 performance reflects resilience and growth, with a focus on expanding revenue streams and market presence through product development and commercialization efforts.
While facing challenges in managing expenses and achieving profitability, the company's strong financial position and revenue guidance revisions signal confidence in its growth trajectory.
By capitalizing on MACI's success, navigating upcoming product launches, and maintaining financial discipline, Vericel is poised for continued success and market expansion in the regenerative medicine space.

Vericel reports robust Q2 earnings, eyes growth through new products

Vericel's strong Q2 performance and raised revenue guidance indicate a positive outlook for the company.
Challenges with NexoBrid distribution and MACI conversion rates require focused strategies for growth.
Opportunities lie in upcoming product launches and targeted sales approaches to drive revenue growth.

Vericel reports record Q3 revenue, raises guidance for 2023

Vericel's Q3 performance was exceptional, setting the stage for continued growth.
The company's strong financial position and product strategies bode well for future success.
Anticipated revenue growth in 2024 and expansion plans signal positive momentum.
Vericel aims for a robust finish in 2023 and sustained growth in 2024.

Vericel (VCEL) posts record Q4 revenue, eyes sustained growth

Vericel (VCEL) delivered robust financial results in Q4 2023, with strong revenue growth, operational efficiency, and positive market feedback on key products.
The company is well-positioned for future growth with new product launches, improved margins, and resolved customer dynamics enhancing market stability.
While challenges exist in maintaining growth momentum and managing quarterly margins, strategic investments and market opportunities offer avenues for sustained success.

Vericel (VCEL) posts stellar Q1 results, eyes market expansion

Vericel delivered a robust performance in Q1 2024, marked by revenue growth, profitability surge, and raised full-year guidance.
The company's strengths lie in margin expansion efforts, strategic investments, and plans for market expansion through new initiatives and surgeon targeting.
Challenges include balancing expenses with profitability targets and ensuring rapid adoption of new products among diverse surgeon segments.
Opportunities abound in operational efficiencies, market expansion strategies, and potential for accelerated growth based on product advantages and market positioning.

Vericel reports record Q2 revenue, eyes growth through new launches

Vericel delivered a strong performance in Q2 2024 with record revenue and profitability, driven by MACI and operational efficiency.
While facing challenges with Epicel revenue variability, the company remains optimistic about growth opportunities and market expansion.
With a focus on product launches, FDA approvals, and financial strength, Vericel is well-positioned for continued growth and success in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vericel Corp (VCEL) CEO Dominick Colangelo on Q4 2019 Results - Earnings Call Transcript

Vericel (VCEL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Vericel (VCEL) Ahead of Earnings?

As of late, it has definitely been a great time to be an investor in Vericel.

Will Vericel Continue to Surge Higher?

Earthstone Energy

MarineMax

Metropolitan Bank Hld

Rite Aid

The optimism regarding small businesses remains near an all-time high albeit a slowing U.S. economy.

Small Business Optimism Rises Amid Coronavirus Fears: 5 Picks

Accuray

MagnaChip Semiconductor

RGC Resources

U.S. stocks are heavily exposed to the domestic economy where data continues to improve. And even if skeptics worry about the virus outbreak, developed markets are more stable than emerging markets during chaotic times.

Virus or No Virus, Investing Case in US Stocks Looks Solid!

YAVNE, Israel and CAMBRIDGE, Mass., Jan.  06, 2020  (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) and its U.S. commercial partner Vericel Corporation (NASDAQ: VCEL) today announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) within the Assistant Secretary for Preparedness and Response (ASPR), a part of the U.S. Department of Health and Human Services (HHS), has begun procuring NexoBrid® for emergency stockpile as part of the HHS mission to build national preparedness for public health medical emergencies. BARDA purchased inventory will be managed by MediWound under vendor managed inventory. The initial BARDA procurement is valued at $16.5 million, with the first delivery of NexoBrid expected by the end of the first quarter of 2020 and additional deliveries occurring over the subsequent five quarters. In addition, BARDA holds an option to procure additional quantities of NexoBrid through funding of up to $50 million. The submission of the Biologics License Application (BLA) for NexoBrid to the U.S. Food & Drug Administration (FDA) is planned for the second quarter of 2020.

BARDA Initiates the Procurement of NexoBrid for Emergency Response

Vericel has been struggling lately, but the selling pressure may be coming to an end soon.

Vericel Sees Hammer Chart Pattern: Time to Buy?

Surprise Jump In Epicel Sales Highlights 'Outstanding' 3Q For Vericel

CAMBRIDGE, Mass., Nov.  06, 2019  (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Sean C. Flynn as Vice President and General Counsel.

Vericel Announces Appointment of Sean C. Flynn as Vice President and General Counsel

Shares jumped following upbeat third-quarter results and a guidance boost.

Why Vericel Stock Is Soaring Today

Vericel Corporation (VCEL) CEO Nick Colangelo on Q3 2019 Results - Earnings Call Transcript

Vericel Corp (NASDAQ: VCEL), a commercial-stage company that specializes in advanced cell therapies for treating patients with knee cartilage defects and severe burn wounds, is investment-worthy, according to H.C.

Vericel Analyst Projects Wound Care Product Sales Will Grow Fivefold By 2025

CAMBRIDGE, Mass. and YAVNE, Israel, Oct.  02, 2019  (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL) and MediWound Ltd. (NASDAQ: MDWD) today announced initiation of the NexoBrid® expanded access treatment protocol (NEXT) to treat burn patients with deep partial- and full-thickness burns in the U.S. during the preparation and review of the NexoBrid Biologics License Application (BLA).

Vericel and MediWound Announce Initiation of U.S. NexoBrid Expanded Access Treatment Protocol

CAMBRIDGE, Mass., Sept.  27, 2019  (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 2019 Cantor Fitzgerald Global Healthcare Conference in New York on Friday, October 4, 2019 at 7:45am Eastern Time.

Vericel to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference on Friday, October 4, 2019

CAMBRIDGE, Mass., Sept.  18, 2019  (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Gerard Michel, CFO & VP of Corporate Development, will present the latest company overview at the Ladenburg Thalmann 2019 Healthcare Conference in New York on Tuesday, September 24, 2019 at 11:00am Eastern Time.

Vericel to Present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019

Vericel Corporation's (VCEL) CEO Nick Colangelo on Q2 2019 Results - Earnings Call Transcript

Vericel's newly acquired burn care product, NexoBrid, is revolutionary, creating a "new paradigm" in burn care.

Target Acquired: The NexoBrid Acquisition And Its Implications For Vericel

Vericel Corporation (VCEL) CEO Nick Colangelo on Q1 2019 Results - Earnings Call Transcript

Vericel (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Vericel (VCEL) Report Negative Earnings Next Week? What You Should Know

After four outstanding earnings day moves, including three gap-ups and third quarter 2018's spectacular +44% price explosion, on February 26, 2019, Vericel eleased its usual impressive 4th quarter earnings, and the stock price went... down.

News for Vericel Stock (VCEL)